Cerus Corporation ( (CERS) ) has released its Q4 earnings. Here is a breakdown of the information Cerus Corporation presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cerus Corporation is a global leader in safeguarding the blood supply, specializing in pathogen protection technologies for blood components used by blood centers, hospitals, and patients. The company has a unique position in the transfusion medicine industry, offering the only FDA and CE marked pathogen reduction system for platelets and plasma.
In its latest financial report for 2024, Cerus Corporation highlighted a robust 15% growth in full-year product revenues and a continued positive trajectory with its fourth consecutive quarter of positive operating cash flows. The company also reiterated its optimistic revenue guidance for 2025, signaling confidence in its growth strategy.
Key financial highlights include a significant improvement in net loss, with a decrease from $37.5 million in 2023 to $20.9 million in 2024. Product revenue reached $180.3 million for the year, driven by strong performance in the platelets business across North America and EMEA. The company also achieved a positive non-GAAP adjusted EBITDA of $5.7 million, surpassing their break-even target.
Despite a decline in government contract revenue due to the completion of certain clinical trials, Cerus managed to reduce its operating expenses by over 8%. The company also increased its cash and cash equivalents to $80.5 million, reflecting solid financial health.
Looking ahead, Cerus Corporation aims to continue its growth momentum with expectations of reaching up to $200 million in product revenue for 2025. The company’s strategic initiatives in expanding its market reach and leveraging its strong product portfolio position it well for future success.
